Sun Young Rha mainly investigates Internal medicine, Cancer, Oncology, Renal cell carcinoma and Surgery. Internal medicine is frequently linked to Gastroenterology in his study. His biological study spans a wide range of topics, including Survival rate, Cancer research and Bioinformatics.
His research investigates the connection with Oncology and areas like Pathology which intersect with concerns in Survival analysis. His Renal cell carcinoma research incorporates elements of Targeted therapy, Clinical trial and Everolimus. His Surgery study integrates concerns from other disciplines, such as Placebo and Capecitabine.
Sun Young Rha focuses on Internal medicine, Cancer, Oncology, Cancer research and Surgery. His Gastroenterology research extends to the thematically linked field of Internal medicine. His work carried out in the field of Cancer brings together such families of science as Survival rate, Pathology and Stage.
Sun Young Rha has included themes like Clinical trial, Phases of clinical research, Trastuzumab, Capecitabine and Advanced gastric cancer in his Oncology study. His Cancer research research integrates issues from Cancer cell, Cell culture, Immunology and Carcinogenesis. His Surgery study combines topics in areas such as Stomach cancer and Adverse effect.
His primary areas of study are Internal medicine, Cancer, Cancer research, Oncology and Chemotherapy. His research on Internal medicine frequently links to adjacent areas such as Gastroenterology. His Cancer research includes themes of Surgical oncology and Cohort.
The study incorporates disciplines such as Cell culture, Cancer cell, Apoptosis and T cell, Immune system in addition to Cancer research. His research in Oncology tackles topics such as Pembrolizumab which are related to areas like Nivolumab. His research integrates issues of Regimen, Trastuzumab and Gene expression profiling in his study of Chemotherapy.
His primary areas of investigation include Internal medicine, Cancer, Oncology, Gastroenterology and Cancer research. All of his Internal medicine and Neutropenia, Chemotherapy, Sunitinib, Oxaliplatin and Hazard ratio investigations are sub-components of the entire Internal medicine study. His Cancer study combines topics from a wide range of disciplines, such as Exosome, Surgical oncology, Surgery, Cytokine and Tolerability.
The various areas that Sun Young Rha examines in his Oncology study include Carcinoembryonic antigen, Clinical trial, Subgroup analysis and Synovial sarcoma. His studies deal with areas such as Survival rate, Nausea, Adverse effect and Progression-free survival as well as Gastroenterology. His Cancer research research incorporates elements of Cell culture, Apoptosis, Immune system and Exon.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha.
Journal of Clinical Oncology (2011)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman.
Lancet Oncology (2013)
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
Niantao Deng;Liang Kee Goh;Hannah Wang;Kakoli Das.
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes
Zhi Jiang Zang;Ioana Cutcutache;Song Ling Poon;Shen Li Zhang.
Nature Genetics (2012)
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano.
The Lancet (2016)
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Keun Seok Lee;Hyun Cheol Chung;Seock Ah Im;Yeon Hee Park.
Breast Cancer Research and Treatment (2008)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta.
The New England Journal of Medicine (2021)
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer;Carlos H. Barrios;Tae Min Kim;Silvia Falcon.
Journal of Clinical Oncology (2014)
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck.
European Urology (2014)
Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer
Chia Huey Ooi;Tatiana Ivanova;Jeanie Wu;Minghui Lee.
PLOS Genetics (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: